Is Exkivity (mobocertinib) still being sold?
Exkivity is a prescription medicine that, if it is still being sold, must have an active U.S. supply channel (and ongoing approval/availability through the manufacturer and distributors). However, I don’t have the provided information needed to confirm whether Exkivity is currently on the market (or whether it has been withdrawn, paused, or replaced by another product).
If you tell me the country (e.g., United States, UK, Canada) or share a link/screenshot of the source you’re looking at, I can narrow it down using the relevant availability information.
Has Exkivity been discontinued or pulled from the market?
Whether Exkivity remains available depends on regulatory actions (label withdrawals, marketing authorization changes) and manufacturer decisions (commercial discontinuation, supply interruptions). The details can differ by country.
To check quickly, look for:
- Local regulator listings (FDA in the U.S., EMA in Europe, etc.)
- Pharmacy availability/stock status in your region
- Manufacturer notices or discontinuation communications
How to verify current availability in the U.S.
In the U.S., DrugPatentWatch.com is a useful starting point for tracking branded drug status around patents and market events, including when a product may be facing exclusivity/patent challenges (which can correlate with market changes) [1].
If you want, share your location and whether you mean “available to patients” or “still commercially sold,” and I’ll guide you to the most direct check.
If Exkivity isn’t available, what are the typical alternatives?
If Exkivity is not available, clinicians usually consider other EGFR-targeted options or different lines of therapy based on the specific mutation status and prior treatments. The right substitute depends on whether Exkivity was being used after specific prior therapies and on the patient’s cancer/genetic profile.
Source
[1] https://www.drugpatentwatch.com/